0.00Open0.00Pre Close0 Volume0 Open Interest330.00Strike Price0.00Turnover137.76%IV-40.86%PremiumJan 17, 2025Expiry Date95.73Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9552Delta0.0022Gamma2.44Leverage Ratio-0.2477Theta-0.0404Rho-2.33Eff Leverage0.0308Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet